ABVD (8 cycles) versus BEACOPP (4 escalated cycles ≥4 baseline): final results in stage III–IV low-risk Hodgkin lymphoma (IPS 0–2) of the LYSA H34 randomized trial-Reference-Cited by-同舟云学术

ABVD (8 cycles) versus BEACOPP (4 escalated cycles ≥4 baseline): final results in stage III–IV low-risk Hodgkin lymphoma (IPS 0–2) of the LYSA H34 randomized trial

Published:2014-08 Issue:8 Volume:25 Page:1622-1628
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Mounier N.,Brice P.,Bologna S.,Briere J.,Gaillard I.,Heczko M.,Gabarre J.,Casasnovas O.,Jaubert J.,Colin P.,Delmer A.,Devidas A.,Bachy E.,Nicolas-Virelizier E.,Aoudjhane A.,Humbrecht C.,Andre M.,Carde P.

Funder

French Programme Hospitalier de Recherche Clinique

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/25/8/1622/16703431/mdu189.pdf

Reference18 articles.

1. Survival in Hodgkin's disease patients—report of 25 years of experience at the Milan Cancer Institute;Bonadonna;Eur J Cancer,2005

2. BEACOPP, a new dose-escalated and accelerated regimen, is at least as effective as COPP/ABVD in patients with advanced-stage Hodgkin's lymphoma: interim report from a trial of the German Hodgkin's Lymphoma Study Group;Diehl;J Clin Oncol,1998

3. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease;Diehl;N Engl J Med,2003